News headlines about Chembio Diagnostics (NASDAQ:CEMI) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chembio Diagnostics earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.2994954673902 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Chembio Diagnostics (NASDAQ CEMI) traded up $0.10 on Friday, reaching $7.30. The company’s stock had a trading volume of 73,817 shares, compared to its average volume of 43,821. The company has a current ratio of 3.54, a quick ratio of 2.19 and a debt-to-equity ratio of 0.01. Chembio Diagnostics has a 1-year low of $5.05 and a 1-year high of $9.20.
In other news, CFO Neil A. Goldman purchased 14,815 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were purchased at an average cost of $6.75 per share, for a total transaction of $100,001.25. Following the purchase, the chief financial officer now directly owns 14,815 shares in the company, valued at approximately $100,001.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.56% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/25/chembio-diagnostics-cemi-given-media-sentiment-score-of-0-14.html.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.